Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)

Bevacizumab is approved as a maintenance treatment in first-line setting in advanced-stage III-IV ovarian cancers, because GOG-0218 and ICON-7 phase III trials demonstrated progression-free survival benefits. However, only the subgroup of patients with high-risk diseases (stage IV, and incompletely...

Descripción completa

Detalles Bibliográficos
Autores principales: Colomban, Olivier, Tod, Michel, Peron, Julien, Perren, Timothy J, Leary, Alexandra, Cook, Adrian D, Sajous, Christophe, Freyer, Gilles, You, Benoit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306189/
https://www.ncbi.nlm.nih.gov/pubmed/32596636
http://dx.doi.org/10.1093/jncics/pkaa026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306189/
https://www.ncbi.nlm.nih.gov/pubmed/32596636
http://dx.doi.org/10.1093/jncics/pkaa026

Ejemplares similares